Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 3Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Solid Tumours 1Solid Tumour 1Solid Tumors, KRAS Mutation 1Solid Tumors 1Solid Tumor, Adult 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Mesothelioma 1Lymphoma, Non-Hodgkin 1Lymphoma 1KRAS p.G12C Mutant Advanced Solid Tumors 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

capivasertib 1atezolizumab 1N1-(3-(dimethylamino)propyl)-N8-hydroxy-2-((naphthalene-1-loxy)methyl)oct-2-enediamide 1N,1,4,4-tetramethyl-8-((4-(4-methylpiperazin-1-yl)phenyl)amino)-4,5-dihydro-1H-pyrazolo(4,3-h)quinazoline-3-carboxamide 1Midazolam 1L19-IL2 immunocytokine 1Itraconazole 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumour × Midazolam × Other solid neoplasm × Clear all
NCT04958226 2024-01-25

A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
21 enrolled
Other solid neoplasm

Solid Tumour

Data powered by HemOnc (CC BY 4.0) Colophon âš¡